In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either placebo or metformin. Fasting levels of glucose, insulin and C peptide were determined at baseline, after 4 months and yearly thereafter for 4 years to assess fasting estimates of beta cell function. The primary endpoint was the fasting C peptide-to-glucose ratio (FCPGR) and secondary measures were the disposition index (DI) and the fasting C peptide (FCP). We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 -5.71).
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In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either placebo or metformin. Fasting levels of glucose, insulin and C peptide were determined at baseline, after 4 months and yearly thereafter for 4 years to assess fasting estimates of beta cell function. The primary endpoint was the fasting C peptide-to-glucose ratio (FCPGR) and secondary measures were the disposition index (DI) and the fasting C peptide (FCP). We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 -5.71).
Compared to placebo, FCPGR increased in the metformin group with 1.48 (95% CI, 1.09 -1.87, P < 0.001). The DI showed comparable results with a treatment effect of 1.50 (95% CI, 1.17 -1.83; P < 0.001). FCP also increased in the metformin group but did not reach statistical significance vs placebo (0.034 nmol, 95% CI, −0.005 -0.072; P = 0.085). Treatment with metformin vs placebo, added to insulin in patients with type 2 diabetes, improves long-term estimates of beta cell function in the fasting state.
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| INTRODUCTION
Metformin is a key drug in the treatment of type 2 diabetes. In the Hyperinsulinaemia: the Outcome of its Metabolic Effects (HOME) study, 1 we showed that metformin improved glycaemic control and decreased insulin requirements compared with placebo in insulintreated patients with advanced type 2 diabetes. In this respect, metformin is generally regarded as an insulin sensitizer. Whether metformin can also improve β-cell function is not clear. In the present analysis of the HOME study, we studied the effects of metformin vs placebo on estimates of fasting β-cell function. In addition, we quantified the durability of metformin's effect on these estimates over a period of 4.3 years.
| METHODS

| Study design and patients
In the HOME study, 390 insulin-treated patients with advanced type 2 diabetes were randomly allocated to either metformin 850 mg 
| Statistical analysis
We used all measurements to assess the effects of metformin vs placebo during the entire follow-up period. To quantify the overall treatment effect over time, we used a linear mixed model, simultaneously assessing the significance of the main time effect, main metformin treatment effect, and interaction of metformin treatment effect with time (Appendix S1).
In addition, we conducted a mediation analysis to assess the indi- and confidence interval (CI), calculated by bootstrapping (details in Appendix S1). Relative to baseline, the treatment effect was 32% (95% CI, 27 to 36).
| RESULTS
The FCP level decreased in the placebo group and increased in the metformin group. Mixed-model results showed a non-significant treatment effect (0.034 nmol [95% CI, -0.005 to 0.072; P = .085), no time effect (0.00 nmol/L/year [95% CI, -0.00 to 0.00]; P = .61), and no timetreatment interaction (0.00 nmol/L/year, 95% CI, -0.00 to 0.00; P = .26).
Relative to baseline, the treatment effect was 7% (95% CI, -1 to 14). 
